Effect of protease inhibitors on apolipoprotein B levels and plasma lipid profile in HIV-1-infected patients on highly active antiretroviral therapy [2]

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 1, 2003, Pages 114-116

  Domingo, Pere ^a   Sambeat, María A ^a   Pérez, Antonio ^a   Ordoñez, Jordi ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LAMIVUDINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; LETTER; LONG TERM CARE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; VIRUS LOAD;

EID: 0038034415     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200305010-00017     Document Type: Letter

References (14)

1. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
2. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-2099.
3. Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin slipase activities in normal subjects. AIDS. 2000;14:51-57.
4. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV proteases inhibitors. AIDS. 1998;12:F51-58.
5. David MH, Hornung R, Fichtenbaum CJ. Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clin Infect Dis. 2002;34:98-102.
6. Liang JS, Distler O, Cooper DA, et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med. 2001;7:1327-1331.
7. Sugiuchi H, Uji Y, Okabe K. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem. 1995;41: 717-723.
8. Hainline A, Karon J, Lippel K. Lipid research clinic program. Manual of laboratory operations, lipid and lipoprotein analysis. 2nd ed. Washington, DC: Government Printing Office, 2000.
9. Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. 4th ed. Oxford: Blackwell Science, 2002.
10. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1993;41(RR-17):1-13.
11. Liao W, Yeung SC, Chan L. Proteasome-mediated degradation of apolipoprotein B targets both nascent peptides cotranslationally before translocation and full-length apolipoprotein B after translocation into the endoplasmic reticulum. J Biol Chem. 1998;273: 27225-27230.
12. Andre P. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci USA. 1998;95:13120-13124.
13. Steinberg D. Lipoproteins and the pathogenesis of atherosclerosis. Circulation. 1989;80:719-723.
14. Moyle GJ, Gazzard BG. A risk-benefit assessment of HIV protease inhibitors. Drug Saf. 1999;20:299-321.